Evaluation of the Reproducibility of the Automated Measurement of the Extent of ILD on Chest CT

NCT ID: NCT06743022

Last Updated: 2026-01-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-24

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. Automated tools are now available to quantify ILD, but there is a lack of data on the reproducibility of this measurement and therefore its accuracy.

Therefore, the purpose of this study is to evaluate the variability of automated ILD quantification on chest CT. Reproducibility will be assessed by repeating chest CT scans and using different tools to measure the extent of disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. In recent years, several tools based on texture analysis or deep learning methods have been developed to provide rapid and accurate automated quantification of ILD extent.

An advantage of automated scoring methods is that they theoretically offer perfect repeatability of measurement. However, this is only true if the measurement is repeated on the same images. Several parameters can alter the appearance of the lungs on scanner images, such as the degree of inspiration or the reconstruction kernel used to reconstruct the images. There is a lack of data on the reproducibility of the whole process of automated ILD quantification and therefore its accuracy.

Therefore, the purpose of this study is to evaluate the variability of automated ILD quantification on chest CT.

Reproducibility will be assessed by repeating chest CT scans and using different tools to measure the extent of disease in patients with ILD from 2 institutions. Chest CT will be repeated the same day. This will allow assessment of the variability of automated measurement of ILD extent between 2 CT scans performed on the same day and when using different software. It will also allow to assess the variability of lung volume between the 2 CT scans and the effect of disease (idiopathic pulmonary fibrosis or connective tissue disease-related ILD) on the reproducibility of ILD quantification.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with interstitial lung disease

Group Type EXPERIMENTAL

Chest CT

Intervention Type DIAGNOSTIC_TEST

Repeated chest CT for automated ILD quantification

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chest CT

Repeated chest CT for automated ILD quantification

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Known interstitial lung disease as part of idiopathic pulmonary fibrosis or connective tissue disease
* Followed in one of the participating hospitals
* Requiring a chest CT as part of a scheduled assessment
* Affiliated to a French national social security
* Informed consent

Exclusion Criteria

* Acute exacerbation of ILD
* Pregnancy
* Inability to hold an apnea for 10 seconds
* Patients in the exclusion period after a previous research
* Need for additional procubitus or expiratory images
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

URC-CIC Paris Descartes Necker Cochin

OTHER

Sponsor Role collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guillaume CHASSAGNON, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Cochin Hospital - AP-HP

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

APHP - Bichat hospital - Radiology

Paris, IDF, France

Site Status RECRUITING

APHP - Bichat hospital - Rheumatology

Paris, IDF, France

Site Status RECRUITING

APHP - Cochin Hospital - Internal medicine

Paris, IDF, France

Site Status RECRUITING

APHP - Cochin Hospital - Pneumology

Paris, IDF, France

Site Status RECRUITING

APHP - Cochin Hospital - Radiology

Paris, IDF, France

Site Status RECRUITING

APHP - Bichat Hospital - Pneumology

Paris, IDF, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Guillaume CHASSAGNON, MD, PhD

Role: CONTACT

+33158414326

Marie BENHAMMANI-GODARD

Role: CONTACT

0033158411190

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marie-Pierre DEBRAY, MD

Role: primary

Pierre-Antoine JUGE

Role: primary

Benjamin CHAIGNE

Role: primary

Isabelle HONORE

Role: primary

Guillaume CHASSAGNON, MD, PhD

Role: primary

Raphaël BORIE

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-A01384-43

Identifier Type: OTHER

Identifier Source: secondary_id

APHP240783

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.